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ABSTRACT 
Objective: The present investigation was undertaken with an objective of formulating oral disintegrating tablets of amlodipine besylate to enhance 
convenience and compliance of the elderly and pediatric patients for better therapeutic efficacy.  
Methods: The tablets were prepared by using direct compression method and evaluated for weight variation, hardness, friability, wetting time, 
disintegration time and in vitro drug release study. Prepared tablets were evaluated for compatibility by Fourier transform infrared spectroscopy. 
Results: Fourier transform infrared spectroscopy studies revealed that there was no physicochemical interaction between amlodipine besylate and 
other excipients. All the tablets hardness was found to be around 3.5 kg/cm2 
Conclusion: The study clearly indicated that the type and concentration of superdisintegrants plays an important role in disintegration and 
dissolution of drug from oral disintegrating tablets. Among all the formulations, the maximum percentage of drug release and less disintegration 
time was found in F9 formulation containing 4% of crospovidone.  
and friability of all the formulations was less than 1%, Drug content in 
all the formulations was found in the range of 97.05% to 99.13%.  
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Solid dosage forms are the most popular and preferred drug delivery 
systems. Most of the oral pharmaceutical dosage forms like 
conventional tablets and capsules are formulated to be swallowed or 
chewed. Many pediatric, geriatric and bedridden patients find 
difficulty in swallowing (i.e., dysphagia) these dosage forms [1]. It is 
estimated that 50 % of the population is affected by this problem 
which results in a high incidence of non-compliance and ineffective 
therapy [2]. The concept of oral disintegrating drug delivery system 
emerged from the desire to improve patient compliance. An oral 
disintegrating tablet offers quick disintegration and dissolution of 
the tablet in the oral cavity within a minute without the need of 
water. According to European pharmacopoeia, oral disintegrating 
tablet should disperse or disintegrate in less than three minutes. The 
medication can be absorbed partially or entirely into the systemic 
circulation from blood vessels in the oral mucosa; it can be 
swallowed as a solution to be absorbed from the gastrointestinal 
tract [3, 4].  
Angina pectoris is chest pain due to ischemia of heart muscle due to 
obstruction or spasm of the coronary arteries. Amlodipine besylate 
is a long-acting calcium channel blocker mainly used in the 
treatment of chronic stable angina vasospastic angina and 
hypertension [5]. Amlodipine is listed in World health organization 
(WHO) under the list of essential medicines as antihypertensive 
medicine in 5 mg tablet. It inhibits the transmembrane influx of 
calcium ion into vascular smooth muscle and cardiac muscle. Its 
efficacy is not only limited to the treatment of cardiovascular 
diseases as it has shown to posses antioxidant activity and plays an 
important role in apoptosis. Peak plasma concentrations are reached 
6-12 h. It has oral bioavailability of 64-90% and half-life of about 30-
50 h [6]. Amlodipine besylate is slightly soluble drug the rate of 
absorption is controlled by the rate of dissolution. The rate of 
dissolution can be increased by the use of super disintegrants [7]. 
Oral disintegrating tablets are designed to be placed in mouth 
allowed to disperse or dissolve in the saliva and then swallowed 
without the aid of water. As the tablet disintegrates in the mouth, 
this could enhance the clinical effect of the drug through pre-gastric 
absorption [8]. The objective of the present study was to deliver the 
drug at a faster rate and to provide immediate onset of action in a 
shorter period of time with improved bioavailability. The basic 
approach in the development of oral disintegrating tablets is the use 
of superdisintegrants like croscarmellose sodium, sodium starch 
glycolate and crospovidone. 
MATERIALS AND METHODS 
Amlodipine besylate was obtained from Yarrow chemicals, Mumbai. 
Sodium starch glycolate, croscarmellose sodium and crospovidone, 
microcrystalline cellulose, and mannitol were purchased from Aman 
scientific industries, Vijayawada. Talc and magnesium stearate were 
purchase from Loba Chemie Pvt. Ltd. All other chemicals/solvents 
used were of analytical grade. 
Estimation of ambroxol hydrochloride  
Lab India double beam UV-Visible spectrophotometer was used to 
estimate amlodipine besylate in pure form and formulations 
developed using various concentrations of super disintegrants at 
237.5 nm.  
An analytical method for construction of calibration curve of 
amlodipine besylate  
100 mg of amlodipine besylate was dissolved in 100 ml of 0.01N 
hydrochloric acid. 10 ml of this solution was further diluted to 100 
ml of 0.01N hydrochloric acid to obtain 100 μg/ml From this 
solution (100 μg/ml) suitable working solutions of different 
concentrations of 3, 6, 9, 12, 15 and 18 μg/ml were prepared. The 
absorbance of these dilutions was measured at the determined 
lambda max of 237.5 nm. The standard graph of concentration 
versus absorbance was then plotted. Each point is an average of 
three determinations. Slope, y-intercept, and regression coefficients 
were calculated [9]. 
Drug-excipient compatibility study 
Fourier transform infrared spectroscopic (FTIR) studies were 
conducted to know the compatibility between drug and excipients. 
In these studies pure amlodipine besylate and its mixture with 
sodium starch glycolate, croscarmellose sodium, and crospovidone 
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were grounded thoroughly with IR grade KBr and then compressed 
in a hydraulic press at a pressure of 10,000 psig, to get a disc. Each 
disc was scanned over a range of 400-4000 cm-1
Preparation of oral disintegrating tablets  
using FTIR 
instrument (FTIR-1600, Shimadzu, Japan). The characteristic peaks 
were observed and recorded. 
Oral disintegrating tablets of amlodipine besylate were prepared by 
direct compression method. All the ingredients listed in table 1 were 
accurately weighed and passed through a # 60 sieve. Amlodipine 
besylate (10 mg) was mixed with various concentrations of super 
disintegrants, microcrystalline cellulose, and mannitol. Then 
magnesium stearate and talc were added to the above blend.  
The flow property of the final blend was determined by measuring 
the angle of repose and carr’s index and they were found to be 
satisfactory to allow the mixture to be directly compressed into 
tablets on a 12-station rotary tablet punching machine (M/s. 
CEMACH Machinery, Co. Pvt. Ltd., India) using 8 mm punch [10]. 
 
Table 1: Composition of oral disintegrating tablets of amlodipine besylate 
Ingredients (mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Amlodipine besylate 10 10 10 10 10 10 10 10 10 
Sodium starch glycolate 2 4 6       
Croscarmellose sodium    2 4 6    
Crospovidone       2 4 6 
Mannitol 66 66 66 66 66 66 66 66 66 
Microcrystalline cellulose 65 63 61 65 63 61 65 63 61 
Sodium sacharin 1 1 1 1 1 1 1 1 1 
Magnesium stearate 3 3 3 3 3 3 3 3 3 
Talc 3 3 3 3 3 3 3 3 3 
Total weight 150 150 150 150 150 150 150 150 150 
 
Micromeritic properties of the blended powder  
Angle of repose  
The angle of repose of powder blend was determined by the fixed 
funnel method. The accurately weighed powder was taken in a 
funnel. The height of the funnel was adjusted in such a way that the 
tip of the funnel just touched the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the 
surface. The diameter of the powder cone was measured and the 
angle of repose was calculated using the following equation [11]. 




Where, θ = angle of repose, 
h = height of the pile, 
r = radius of the pile base 
Bulk Density and tapped density 
A quantity of 2 g of powder from each formula, previously lightly 
shaken to break any agglomerates formed was introduced into a 10 
ml measuring cylinder. After the initial volume was observed then 
calculate bulk density using the following formula [11]. 
Bulk density =
weight of the powder
bulk volume
 
The cylinder was allowed to fall under its own weight onto a hard 
surface from the height of 2.5 cm at 2 second intervals. The tapping 
was continued until no further change in volume was noted. Tapped 
density was calculated using the following formula [11]. 
tapped density =
weight of the powder
tapped volume
 
Compressibility index  
The compressibility index of the powder blend was determined by 
Carr’s compressibility index [11]. 
Carr′s index =
tapped density − bulk density
tapped density
× 100 
Evaluation of amlodipine besylate oral disintegrating tablets 
Weight variation test  
To study weight variation, 20 tablets of each formulation were 
weighed using an electronic balance. Average weight was calculated 
then individual tablet weight was compared with average weight 
[12].  
Tablet hardness and friability 
For each formulation, the hardness of 6 tablets was determined 
using the Monsanto hardness tester. Friability of tablets was 
measured by using Roche Friabilator. Friability was evaluated from 
the percentage weight loss of 10 tablets tumbled in a friabilator at 
25 rpm for 4 min. The tablets were deducted and the loss in weight 
caused by fracture or abrasion was recorded as the percentage 
weight loss. Friability below 1% was considered acceptable [12].  
Friability =
Initial weight − Final weight
Initial weight
× 100 
Uniformity of drug content 
10 Tablets were weighed from each formulation and triturated in a 
mortar to a fine powder. Powder equivalent to 10 mg of amlodipine 
besylate was extracted in 10 ml of methanol and liquid was filtered. 
The drug content was determined by measuring the absorbance at 
237.5 nm (using a UV-Visible spectrophotometer, Lab India) after 
appropriate dilutions with methanol. The drug content was 
determined using a calibration curve. The mean percentage drug 
content was calculated as the average of three determinations. 
Wetting time  
The wetting time of the tablets can be measured using a simple 
procedure. Five circular tissue papers of 10 cm diameter are placed 
in a petridish with a 10 cm diameter. 10 ml of water containing 
amaranth, a water-soluble dye is added to petridish. A tablet is 
carefully placed on the surface of the tissue paper. The time required 
for water to reach the upper surface of the tablet is noted as a 
wetting time [13] 
Water absorption ratio  
A piece of tissue paper folded twice was placed in a small petridish 
containing 6 ml of water. A tablet was put on the tissue paper and 
allowed to completely wet. The wetted tablet was then weighed. Water 








 = Weight of tablet after water absorption 
b = Weight of tablet before water absorption  
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In–vitro dispersion time  
The amount of saliva available in the oral cavity is very limited 
(usually less than 6 ml). In a simplest method, 6 ml of phosphate 
buffer of pH 6.8 was taken in a 25-ml measuring cylinder. The 
temperature was maintained at 37 ± 2° C. An oral disintegrating 
tablet was placed into it and time required for complete 
disintegration of the tablet was noted [15]. 
In vitro drug release studies  
In vitro drug release studies were carried out using Type II-USP 
dissolution test apparatus, Paddle (DBK dissolution testing apparatus, 
Mumbai, India) at 75 rpm. The dissolution medium consists of 500 ml 
of 0.01N hydrochloride acid. The medium was maintained at 37±0.5 
°C. Aliquot (5 ml) of the solution was collected from the dissolution 
apparatus at 5, 10, 15, 20, 25 and 30 min. and replenishment with an 
equal volume of fresh dissolution medium. The withdrawn samples 
were analyzed by an UV-Visible spectrophotometer (Lab India) at 
237.5 nm using 0.01N hydrochloride acid as a blank. Aliquots were 
withdrawn from a zone midway between the surface of dissolution 
medium and the top of rotating paddle [16]. 
RESULTS AND DISCUSSION 
An analytical method for construction of a calibration curve  
In order to conduct the in vitro drug dissolution studies calibration 
curve was plotted to determine R2
  
 and the equation of straight line is 
used to calculate drug release. Calibration curves of amlodipine 
besylate in 0.01 N hydrochloride acid was constructed at lambda 
max of 237.5 nm and is shown in the fig. 1 
 
Fig. 1: Calibration curve of amlodipine besylate 
 
Table 2: Micromeritic properties of the blended powder 
Formulation Bulk density (gm/cc) Tapped density (gm/cc) Carr’s index (%) Hausner ratio Angle of repose (θ) 
F1 0.43±0.07 0.52±0.02 16.09±0.04 1.19±0.02 27.5±0.01 
F2 0.44±0.05 0.51±0.03 14.06±0.03 1.16±0.01 29.0±0.04 
F3 0.45±0.01 0.52±0.05 14.12±0.04 1.16±0.01 27.7±0.03 
F4 0.43±0.09 0.52±0.08 16.39±0.03 1.19±0.02 29.7±0.04 
F5 0.43±0.03 0.51±0.09 15.44±0.02 1.18±0.03 27.1±0.03 
F6 0.44±0.03 0.51±0.09 12.74±0.07 1.14±0.02 28.3±0.06 
F7 0.42±0.04 0.51±0.04 16.69±0.09 1.20±0.07 27.5±0.04 
F8 0.42±0.05 0.50±0.04 15.71±0.03 1.18±0.03 28.0±0.01 
F9 0.44±0.06 0.51±0.04 12.74±0.01 1.14±0.04 27.7±0.03 
All the values are expressed as mean±SD, where n=3. 
 
Oral disintegrating tablets of amlodipine besylate were prepared by 
direct compression method employing different concentrations of 
sodium starch glycolate, croscarmellose sodium and crospovidone. A 
total of nine formulations were designed. The formulation F1, F2, F3 
having sodium starch glycolate as superdisintegrants. Formulation 
F4, F5, F6 having croscarmellose sodium as superdisintegrants. 
Formulations F7, F8, F9 having crospovidone as superdisintegrants. 
The flow properties of the powder blend were measured before 
compression. Results were shown in the table-2. The angle of repose 
values ranged from 27.1±0.03 to 29.7±0.04. Compressibility index 
and Hausner’s ratio values were ranged from 12.74±0.01 to 
16.69±0.09 and 1.14±0.02 to 1.20±0.07 respectively. Low Hausner’s 
ratio (less than 1.25), compressibility index (less than 17 %) and 
angle of repose (less than 30°) indicated that the powder blend had 
good free-flowing property. 
Oral disintegrating tablets of amlodipine besylate were prepared by 
direct compression technique. The prepared tablets were evaluated 
for different physicochemical properties and results were depicted in 
tables 3 and 4. All the tablets passed weight variation test as the % 
weight variation was within the pharmacopoeial limits of±7.5%. 
Hardness (3.6±0.11 to 3.9±0.12 kg/cm2
  
) and friability was less than 
1% in all the formulations indicated that tablets had good mechanical 
resistance. Uniformity of the amlodipine besylate was determined by 
double bean UV spectrophotometer (LABINDIA), the content of 
amlodipine besylate was found within official limits. Drug content of 
all the tablets was found in the range of 97.05% to 99.13%. 
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Table 3: Evaluation parameters of oral disintegrating tablets of amlodipine besylate 
Formulation Weight variation (mg)* Hardness (kg/cm2 Friability (%) )# Content uniformity (%) 
F1 149.50±0.5 3.6±0.11 0.81 97.05 
F2 150.50±0.2 3.7±0.15 0.64 97.11 
F3 149.75±0.5 3.9±0.12 0.51 98.0 
F4 149.25±0.9 3.7±0.16 0.62 99.0 
F5 150.35±0.5 3.8±0.18 0.57 97.0 
F6 149.22±0.9 3.6±0.18 0.65 98.0 
F7 150.37±0.1 3.7±0.19 0.82 97.22 
F8 149.58±0.2 3.6±0.15 0.8 98.82 
F9 150.32±0.3 3.8±0.14 0.64 99.13 
All the values are expressed as mean±SD, where* n=20 and # n=3 
 
Table 4: Evaluation parameters of oral disintegrating tablets of amlodipine besylate 
Formulation Wetting time (sec) Water absorption ratio In vitro dispersion time (sec) % of drug release (30 min.) 
F1 91.0±1.2 56.2±0.2 36.55±2 57.90 
F2 60.15±1.5 64.2±0.5 34.3±1.5 67.50 
F3 47.35±1.9 86.6±0.2 32.9±2.5 80.09 
F4 60.09±0.8 57.14±0.3 31.1±1.5 76.56 
F5 55.61±1.3 75.0±0.1 30.8±1.3 81.76 
F6 55.0±1.9 87.5±0.3 29.5±1.6 93.72 
F7 40.20±1.7 53.3±0.4 30.3±1.5 74.50 
F8 38.94±1.9 73.33±0.5 29.80±2 85.29 
F9 24.48±1.1 92.85±0.9 28.2±2.2 98.92 
All the values are expressed as mean±SD, where n=3. 
 
Wetting time evaluation was used to predict the penetration of 
medium into the structure of oral disintegrating tablets. The 
results of wetting time evaluation were shown in table 4. The 
wetting time of all the formulations was found to be in the range of 
24.48±1.1 to 91.0±1.2 sec. Water absorption ratio was important 
parameter for understanding the capacity of disintegrant to swell 
in the presence of a little amount of water. The difference in water 
absorption ratio among the formulations was due to water uptake 
and swelling behaviour of superdisintegrants. Water absorption 
ratio of all the formulation was found to be in the range of 
56.2±0.2 to 92.85±0.9. In vitro dispersion time is used to measure 
the time required by the tablets to produce complete dispersion. 
The most important parameter that needs to be optimized in the 
development of oral disintegrating tablets is the disintegration 
time of the tablets. As the concentration of super disintegrant 
increases the disintegration time decreases. In vitro dispersion 
time of all the formulated tablets was found to be within 40 sec. 
Fast disintegration was observed with crospovidone as it has very 
high capillary activity and hydration capacity. The water uptake 
stretches out the folded molecular chains lying between the 
crosslinks, causing an instant expansion of the polymer. The 
increase of volume creates an internal pressure exceeding that of 
tablet strength, which resulted in fast disintegration of tablet. The 
dissolution study of oral disintegrating tablets was performed in 
0.01N hydrochloric acid using USP type II apparatus at 75 rpm. 
The comparative drug release profile was shown in fig. 2. 
  
 
Fig. 2: Comparative in vitro dissolution profile of all the formulations (mean±SD, n=3) 
 
The dissolution rate was found to be comparatively less for the 
formulations containing sodium starch glycolate. The maximum 
increase in the dissolution rate was observed with crospovidone. 
The order of dissolution rate with various superdisintegrants was 
found to be crospovidone>croscarmellose sodium>sodium starch 
glycolate. The maximum percentage of drug release was found in F9 
formulation containing 4% of crospovidone, which shows 82.2% of 
drug release at the end of 10 min and 98.92% at the end of 30 min. 
Based on above results formulation F9 was selected as best 
formulation. 
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FTIR studies  
The results of FTIR spectrum of pure amlodipine besylate and 
optimized formulation F9 was shown in fig. 3 and 4 respectively. 
The characteristic peaks of the drug were observed in the spectra 
of drug and optimized formulation F9 indicates that there is no 




Fig. 3: FT-IR spectrum of pure amlodipine besylate 
 
 
Fig. 4: FT-IR spectrum of oral disintegrating tablet of amlodipine besylate (F9) 
 
CONCLUSION 
Oral disintegrating tablets of amlodipine besylate were successfully 
prepared by direct compression method using crospovidone, 
croscarmellose sodium and sodium starch glycolate. All the oral 
disintegrating tablets possessed good micromeritic, physicochemical 
and dissolution properties. Among the nine formulations prepared, 
the formulation F9 containing 4% of Crospovidone gave higher in 
vitro drug release of 98.92% at the end of 30 min. The developed 
oral disintegrating tablets may provide quick onset of action with 
improved oral bioavailability and enhanced patient compliance and 
therapeutic efficacy.  
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